NICE changes its mind on Novartis’ progressive MS drug MayzentUK cost-effectiveness agency NICE has backed Novartis’ Mayzent for secondary progressive multiple sclerosis (SPMS), after turning it down Share XNICE changes its mind on Novartis’ progressive MS drug Mayzenthttps://pharmaphorum.com/news/nice-changes-its-mind-on-novartis-progressive-ms-drug-mayzent/
NICE says no to Novartis’ Mayzent in secondary progressive MSThere isn’t enough evidence to back the use of Novartis Mayzent for secondary progressive multiple sclerosis on the Share XNICE says no to Novartis’ Mayzent in secondary progressive MShttps://pharmaphorum.com/news/nice-says-no-to-novartis-mayzent-in-secondary-progressive-ms/
Novartis’ Mayzent, Roche’s Polivy head latest crop of CHMP approvalsThe EMA’s human medicines advisory committee recommended approval of five novel medicines at its November meeting, including Novartis’ Share XNovartis’ Mayzent, Roche’s Polivy head latest crop of CHMP approvalshttps://pharmaphorum.com/news/novartis-mayzent-roches-polivy-head-latest-crop-of-chmp-approvals/
